David R. Lynch, MD, PhD

Articles

Mechanistic Action and FDA Outlook for Omaveloxolone in Friedreich Ataxia: David R. Lynch, MD, PhD

September 27, 2021

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed whether omaveloxolone’s therapeutic benefit is enough for it to become the first approved therapy for Friedrich ataxia. [WATCH TIME: 2 minutes]

Omavelexolone’s Potential in Friedrich Ataxia: David R. Lynch, MD, PhD

September 24, 2021

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed his presentation at MDS 2021, which highlighted the therapeutic benefit of omaveloxolone in Friedrich ataxia. [WATCH TIME: 2 minutes]